Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 2003 Sep 17;100(20):11309–11314. doi: 10.1073/pnas.1834451100

Electron microscopic evidence for nucleation and growth of 3D acetylcholine receptor microcrystals in structured lipid–detergent matrices

Yoav Paas *,, Jean Cartaud , Michel Recouvreur , Regis Grailhe *, Virginie Dufresne *, Eva Pebay-Peyroula §, Ehud M Landau , Jean-Pierre Changeux *,
PMCID: PMC208753  PMID: 13679581

Abstract

Nicotinic acetylcholine receptors (AChRs) belong to a superfamily of oligomeric proteins that transduce electric signals across the cell membrane on binding of neurotransmitters. These receptors harbor a large extracellular ligand-binding domain directly linked to an ion-conducting channel-forming domain that spans the cell membrane 20 times and considerably extends into the cytoplasm. Thus far, none of these receptor channels has been crystallized in three dimensions. The crystallization of the AChR from Torpedo marmorata electric organs is challenged here in lipidic–detergent matrices. Detergent-soluble AChR complexed with α-bungarotoxin (αBTx), a polypeptidic competitive antagonist, was purified. The AChR–αBTx complex was reconstituted in a lipidic matrix composed of monoolein bilayers that are structured in three dimensions. The αBTx was conjugated to a photo-stable fluorophore, enabling us to monitor the physical behavior of the receptor–toxin complex in the lipidic matrix under light stereomicroscope, and to freeze fracture regions containing the receptor–toxin complex for visualization under a transmission electron microscope. Conditions were established for forming 2D receptor–toxin lattices that are stacked in the third dimension. 3D AChR nanocrystals were thereby grown inside the highly viscous lipidic 3D matrix. Slow emulsification of the lipidic matrix converted these nanocrystals into 3D elongated thin crystal plates of micrometer size. The latter are stable in detergent-containing aqueous solutions and can currently be used for seeding and epitaxial growth, en route to crystals of appropriate dimensions for x-ray diffraction studies.

Keywords: nicotinic acetylcholine receptor, crystallization, structure


To date, the crystal structures of ≈50 integral membrane proteins have been determined at atomic resolution. This result is in stark contrast to their abundance, as they comprise one-third of all gene products. Inherent difficulties with high-level expression, purification, and, particularly, crystallization of integral membrane proteins account for this situation (1). Receptor channels that selectively regulate transport of ions across the cell membrane are large membrane-spanning oligomers. Among them are the pentameric ligand-gated ion channels (also termed the Cys-loop receptors), which mediate and modulate fast cell–cell communication throughout the nervous system.

The first and most extensively studied pentameric ligand-gated ion channel is the acetylcholine receptor (AChR; reviewed in refs. 24). The AChR isolated from the electric organs of Torpedo ray is available in milligram amounts suitable for crystallization experiments. It is a pseudosymmetrical glycoprotein of ≈290 kDa comprised of five subunits (2αβγδ) and carries two ACh-binding sites at the α–γ and α–δ boundaries (2, 3). So far, it was possible to organize this oligomeric protein only in tubular 2D crystals within receptor-rich membrane fragments (5, 6). These crystals enabled the collection of electron diffraction data at 9-Å down to 4-Å resolution (refs. 7 and 8 and references therein).

As with other pentameric ligand-gated ion channels, a few reasons account for the receptor's difficulty to form ordered 3D crystals that are necessary for x-ray structure determination at atomic resolution. First, it is a highly amphiphilic oligomer, characterized by a large hydrophobic region that consists of 20 transmembrane segments and two hydrophilic domains: (i) a ligand-binding domain that protrudes extracellularly by ≈8 nm and displays an 8- to 9-nm diameter (7) and (ii) an intracellular domain that protrudes by ≈4.5 nm into the cytoplasm and displays a diameter that narrows from ≈8 to ≈4 nm (7). Second, it is an allosteric protein that interconverts spontaneously between at least three alternative, discrete conformations: resting, active, and desensitized states (2, 3). Third, the receptor is glycosylated with high-mannose and complex oligosaccharides (9).

Here, we report the 3D crystallization of the Torpedo AChR by extending a methodology successfully used with several archaeal rhodopsins (1015) which, unlike the AChR, are small proteins mostly embedded in the lipid bilayer.

Materials and Methods

Preparation of AChR–α-bungarotoxin (αBTx) Complexes for Crystallization. All purification steps were performed at 4°C and included, with one exception, protease inhibitor mixture (Sigma). Preparations of Torpedo AChR-rich membranes and removal, by alkaline treatment, of the 43-kDa rapsyn protein that is associated with the receptor, were performed basically as described (16). The alkaline-treated membranes (1 mg/ml) were then solubilized in buffer containing 5 mM Hepes, 80 mM NaCl, and 6.5 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS; pH 7.4). The CHAPS-soluble AChR was immobilized on affinity resin. The affinity resin was prepared by reacting Affi-Gel 102 (Bio-Rad) with N-acetyl-dl-homocysteine thiolactone (Sigma) to form sulfhydryl-terminal-crosslinked agarose (17), which then was reacted with bromo-acetylcholine bromide (18) as described (19).

After extensive wash of the AChR-bound resin with solubilization buffer, tetramethylrhodamine–αBTx conjugate (Molecular Probes; ≈2-fold molar excess over αBTx-binding sites) was cycled slowly through the column until it diffused homogeneously throughout the resin. After a further few hours of incubation, the mobile AChR–αBTx complexes and the free αBTx were collected and subjected to concentration by using centrifugal filter device with a 100-kDa nominal molecular mass limit (Amicon, Millipore). Removal of free αBTx was obtained after repetitive dilution/concentration steps, which were performed in the absence of protease inhibitors. Note that, throughout the purification process, the concentration of αBTx was systematically kept above 6 μM. Finally the AChR–αBTx was concentrated to 20–25 mg/ml, and DTT was added to maximal 1 mM concentration to obtain homogenous light AChR form (monomeric pentamers) (20, 21). Notably, stopped-flow experiments indicate that CHAPS stabilizes the receptor population in a high-affinity desensitized state progressively with the increase in detergent:lipid ratio (data not shown and ref. 22). Conclusively, here, during unbinding and displacement of the resin-immobilized acetylcholine by the toxin, the receptor remains in its desensitized state. This conclusion is in line with previous studies that showed that αBTx or other α-toxins bind with a very high affinity (Kd in picomolar range) to AChR that is solubilized by, and kept in, desensitizing detergents (e.g., refs. 23 and 24 and references therein).

Crystallization. Purified AChR–αBTx complexes were incorporated with monoolein (monooleoyl-rac-glycerol [C18:1c9]; NU CHEK) as described (25) at receptor concentration of 8–10 mg/ml. The resulting lipidic phase was then overlaid with solutions of various chemical compositions. Birefringent red patches were obtained at 20°C with an overlaying solution containing 0.1 M sodium cacodylate, 18% wt/vol polyethylene glycol (PEG) 8000, 0.2 M calcium acetate, 0.5 mM DTT, and 0.02% sodium azide (pH 6.5–6.8). As soon as birefringence reached its maximum (usually within 2–6 wk, depending on the concentration of protein in the patch), the overlay solution was exchanged by liquefaction solution containing 0.1 M Hepes, 28% wt/vol PEG 400, 0.2 M calcium chloride, 3.5–6.5 mM CHAPS, 0.5 mM DTT, and 0.02% sodium azide (pH 7.2). The samples were occasionally transferred to 27–30°C and inspected routinely under a light microscope. With time, the highly viscous and transparent cubic phase became turbid and then turned into an emulsion containing red micrometer-sized crystals. The latter were harvested with nylon loops, soaked in liquefaction solution supplemented with 30% (wt/wt) glycerol, and cryo-cooled rapidly to ≈100 K in liquid propane. Crystals were examined for diffraction at beam line ID14 of the European Synchrotron Radiation Facility (ESRF), Grenoble, France.

Electron Microscopy (EM). For EM studies, the entire lipidic phase was removed from the tube with a fine spatula, and the red birefringent patches were separated from the bulk lipidic matrix by using microtools. A decrease in birefringence that reflects loss of crystallinity was observed during these mechanical manipulations. The resulting material was gently compressed and flattened between two copper-made specimen holders (Bal-Tec, Liechtenstein), cryo-cooled in liquid propane and quickly transferred to liquid nitrogen. Specimens were fractured at –150°C, shadowed with platinum, and coated with carbon in a Balzers 310 apparatus (Balzers), all under high vacuum conditions as described (26) but with no prefixation of the red birefringent material. The resulting replicas were cleaned, placed on collodion-coated EM grids, and inspected in a CM 12 electron microscope (Philips, The Netherlands) operating at 80 keV. Micrographs were taken on Kodak Electron Image plates.

Results

Purification of AChR–αBTx Complexes for Crystallization. The crystallization experiments presented here use AChR molecules associated with tetramethylrhodamine–αBTx conjugates. αBTx is a highly specific competitive antagonist of the Torpedo AChR (27). Like other α-neurotoxins (2832), αBTx binds to skeletal muscle AChRs, blocking thereby the postsynaptic activity in the neuromuscular junction. Two αBTx molecules can specifically bind one receptor heteropentamer. The affinity of the toxin for both sites of a detergent-soluble Torpedo AChR is similar and very high (23), displaying equilibrium dissociation constant (Kd) in the picomolar range. The half-life of the complex is >10 days (23). Accordingly, no detachment of the toxin from the receptor was observed during the preparation of AChR-αBTx complexes. Lane 5 of Fig. 1A shows the bands corresponding to the Torpedo receptor subunits and the rhodaminylated αBTx. We refer to this detergent-soluble purified complex as a desensitized, αBTx-bound stable receptor (see Materials and Methods).

Fig. 1.

Fig. 1.

Incorporation of AChR–αBTx complexes into a lipidic 3D matrix. (A) Reducing SDS-polyacrylamide gel (9%) showing the purification steps: lane 1, molecular mass markers; lane 2, receptor-rich membranes; lane 3, pH 11-treated receptor-enriched membranes; lane 4, CHAPS-solubilized receptor; lane 5, purified fraction. αBTx (8.5 kDa) that migrates at the front and the receptor subunits are indicated. Shown is a gel stained by Coomassie brilliant blue. (B) Space-filling model of a MO molecule. Dark and light spheres correspond to oxygen and carbon atoms, respectively. (C) MO mixed with the protein-carrier buffer at MO:buffer ratio of 6:4 (wt/wt). The inner diameter of the glass tube is 2.5 mm. (D) Example of purified AChR–αBTx complexes concentrated inside the lipidic phase; the red color corresponds to tetramethylrhodamine that is covalently attached to the toxin. Shown is a picture taken under regular light. (E) The same sample as shown in D but under polarized light. Note that only regions that contain receptor–toxin complexes become birefringent. Also, there are regions that are red but not birefringent; their portion may vary between ≈5% and 40% of the total incorporated AChR–αBTx.

Incorporation of AChR–αBTx Complexes in a Bilayer-Based 3D Matrix. Monoolein (MO) is a lipid whose small, uncharged hydrophilic glycerol head is linked to an 18-carbon-long alkenyl chain via an ester bond (Fig. 1B). A cis-double bond between C9 and C10 confers to the alkenyl chain a kink, which contributes to the wedge shape of this lipid. Fig. 1C shows the lipidic phase formed on mixing MO with a buffer devoid of protein. This phase is highly viscous, isotropic, transparent, and nonbirefringent, indicative of a cubic phase that consists of curved bilayers organized in three dimensions (refs. 25 and 33; see ref. 34 for a schematic representation).

Fig. 1D shows AChR–αBTx complexes incorporated and concentrated inside the MO cubic phase. The red color corresponds to tetramethylrhodamine that is covalently attached to αBTx. Tetramethylrhodamine is a photostable fluorophore that absorbs at 555-nm and emits at 580-nm wavelengths. Hence, the physical appearance of, and changes in, the AChR–αBTx complexes inside the lipidic cubic phase could be monitored by using a light stereomicroscope. Numerous conditions for crystallization were tested by overlaying the cubic phase with solutions of various chemical compositions. Because the aqueous compartments of the cubic phase are sufficiently large to accommodate hydrophilic molecules as large as lysozyme (35), small solutes could penetrate into the cubic phase and interact with the hydrophilic portions of the incorporated receptor–toxin complexes. Under most conditions screened for crystallization, no diffusion of red material from the viscous lipidic phase to the overlaying phase was observed, indicating a stable receptor–toxin complex.

Specific crystallization conditions rendered the red patches birefringent, as visualized under cross polarizers (Fig. 1E). This finding indicates polycrystallinity (36) and formation of intermolecular contacts.

EM Reveals Dense 2D AChR Lattices That Are Stacked in the Third Dimension. To directly visualize the organization of AChR–αBTX complexes in the lipidic phase, the red-labeled patches were inspected under electron microscope (see Materials and Methods). Fig. 2A shows a region containing nanometer-sized polygonal bodies reminiscent of nanocrystals. Some of these bodies are embedded in the lipidic matrix and protrude toward the viewer whereas others detached probably owing to the fracturing action, leaving behind depressions with a print of their shape.

Fig. 2.

Fig. 2.

Transmission electron micrographs of regions containing AChR–αBTx complexes. (A) Freeze fracture of red-labeled birefringent regions such as those shown in Fig. 1 D and E reveals many nanocrystals. Note that the upper left corner corresponds to a flat lipidic surface devoid of nanocrystals. (Scale bar = 0.5μm.) (B) Top view of a freeze-fracture plane showing segregation between particle-containing (upper part) and particle-devoid (lower part) regions. The arrows indicate six of numerous small regions consisting of spherical particles that are densely packed as highly ordered aggregates reminiscent of nuclei and tiny nanocrystals. The terrace-like architecture depicted in the lower part corresponds to ≈4-nm-width layers stacked on top of each other. (Scale bar = 50 nm.) The white/grayish areas are shadowed by platinum.

Fig. 2B shows a more detailed fracture plane that exhibits segregation between two types of architectures. The upper part depicts densely packed, spherical particles of an ≈8- to 9-nm diameter. This diameter is in accord with the size previously shown for the AChR in membranes prepared from the Torpedo electric organs (ref. 7 and references therein, and ref. 26). Some small regions displaying highly ordered aggregates could clearly be seen (Fig. 2B, upper part). The lower part does not contain any particles as it reflects lamellar-crystalline organization (34), characterized by lipidic lamellae stacked on top of each other, with no sufficient water in between to accommodate the hydrophilic portions of the receptor.

Freeze-fracture through rhodamine-labeled birefringent material also revealed numerous highly dense 2D lattices of spherical particles (e.g., Fig. 3). As before, the diameter of the particles fits with the molecular size of the Torpedo AChR. Despite the low resolution of the EM technique used here, the pit of the receptor could readily be identified as a black spot surrounded by the receptor subunits (Fig. 3), giving rise to the doughnut-like shape typical of the AChR (57, 26). Careful inspection of the transmission EM micrographs indicates defects in these lattices: for instance, collapse of receptor particles (e.g., Fig. 3A), dislocations (e.g., Fig. 3B), and cracks that could readily be distinguished from regular facets (e.g., Fig. 3C).

Fig. 3.

Fig. 3.

AChR–αBTx complexes are organized in 2D lattices. (A) Top view of a nanometer-sized crystal reflecting nucleation of receptor–toxin complexes inside the MO cubic phase. The small arrow indicates a receptor molecule that appears like a doughnut displaying five subunits surrounding a black pit. The diameter of this receptor is ≈9 nm. The large arrow indicates a receptor molecule that collapsed and coalesced with the neighboring right-handed receptor. (B) Top view of a region showing hundreds of spherical particles organized side by side in linear rows. These particles correspond to AChR molecules, as discussed in the text. The black arrow in the upper right corner points to a defect propagating along the nanocrystal. The black and white arrows at the bottom left corner pointto a contact area between two nanocrystals. Regular facets can be seen at the upper and lower edges. (C) A wide crack along a nanocrystal is pointed by the arrow. A regular facet can be visualized at the lower edge. In all panels, the scale bars correspond to 50 nm, and the white/grayish areas are shadowed by platinum.

Fracturing perpendicularly to the planes shown in Fig. 3 exposed highly dense layers that are stacked on each other (e.g., Fig. 4A). Despite the heavy damages seen in this fracture plane, single AChR molecules that were split along their longitudinal axis were visualized (Fig. 4B). These molecules display the shape and dimensions typical of the receptor in tubular 2D crystals (37) (Fig. 4, compare B to C). The receptor molecules are packed tail to tail (Fig. 4B) and probably interact via their heads to form the multilayer architecture seen in Fig. 4A, as illustrated in Fig. 4D.

Fig. 4.

Fig. 4.

AChR–αBTx complexes are organized in layers stacked in the third dimension. (A) Freeze-fracture plane passing through a mid-longitudinal axis of the receptor molecules exposes a multilayer organization. The grayish ruptures (one is indicated by a white asterisk) correspond to pieces that were torn apart from the fracture plane. The region indicated by the white arrow is magnified in B. Note that many receptor molecules collapsed, probably because of the fracturing through hard proteinaceous material. The receptor molecules are darkened, and the pits are white/grayish. (Scale bar = 50 nm.) (B) Magnification of six “U-shaped” constituents of the region indicated in A by a white arrow. These receptor molecules are arranged side by side and are tightly packed tail to tail. For convenience, a white line delineates the boundaries of the middle receptor dimer. The white arrow indicates the pit of a receptor molecule as can be compared with the pit shown in C. (Scale bar = 50 Å.) (C) Side view of AChR molecules as seen in a portion of a tubular 2D crystal previously obtained from pH 11-treated membranes. [Reproduced with permission from ref. 37 (Copyright 1988, Nature Publishing Group, www.nature.com).] The arrow points to the receptor's pit. (Scale bar = 50 Å.) (D) Scheme illustrating the packing pattern of the receptor molecules as concluded from A and B. The arrow indicates an initiation point for a fracture that would provide a top view of the lattice, as observed in many fracture planes (e.g., Fig. 3).

Emulsification of the Lipidic Matrix Triggers the Formation of AChR Microcrystals. To obtain crystals that are larger than those shown in Figs. 2 A and 3, the hydration level of the cubic phase was increased and detergents were used to perturb its highly viscous consistency. Elongated thin crystal plates appeared in the resulting emulsion. Such reproducible crystals (e.g., Fig. 5A) are homogeneously red and display clear facets. Stronger color is observed for the larger crystals, which consist of a larger number of AChR–αBTx complexes. These crystals appear birefringent under crossed polarizers (Fig. 5B), indicating some high degree of order.

Fig. 5.

Fig. 5.

Emulsification of the lipidic phase results in growth of micrometersized AChR–αBTx crystals. (A) A few thin crystal plates that grew on slow liquefaction of MO cubic phase that harbored AChR–αBTx nanocrystals. Shown is a picture taken under a regular light. The dimensions of the largest crystal are: 300 μm × 30 μm ×≈15 μm. (B) The same crystals as shown in A but under polarized light.

Note that, in a separate set of experiments (performed as in ref. 23), no detachment of [125I]αBTx from preformed AChR–[125I]αBTx complexes was detected under the crystallization and emulsification conditions.

Discussion

Reconstitution of the Torpedo AChR in MO-based 3D matrix allowed here the nucleation and crystallization of a glycosylated full-length receptor channel in three dimensions. Depending on hydration, temperature, and pressure, MO can form a variety of mesophases, including the lamellar, cubic, and inverted hexagonal phases (33, 34). In the cubic phase, the MO bilayers are isotropically curved in 3D space, and they separate between two channel-like aqueous compartments. A reconstituted membrane protein can diffuse laterally in the three dimensions of the cubic phase, provided that the aqueous compartments of the cubic phase are sufficiently large to accommodate the extra-membranous portions of the incorporated protein (10, 38). Yet, rotational and translational constraints that are dictated by the cubic phase architecture lead to ordered nucleation and crystallization, possibly as proposed for bacteriorhodopsin (34, 39).

The diameter of the water channels in pure MO-water cubic phase at room temperature is ≈50 Å. Thus, a major question in the current study is how the Torpedo AChR, which harbors an extracellular domain ≈80–90 Å in diameter and protrudes from the lipidic bilayer by ≈80 Å, can be incorporated in such a lipidic cubic phase. Moreover, the diameter of the AChR–αBTx complex would be even larger because α-toxins probably dock at the exterior wall of AChRs, as predicted by computational models (4043) that became feasible only after the x-ray structure of a water-soluble ACh-binding protein (44) was determined at atomic resolution (45). To accommodate such a large domain, either the cubic phase has to undergo a local structural change, or it may undergo a phase transition and adopt a noncubic structure. One can therefore anticipate that the lamellar liquid-crystalline phase may constitute a favorable lipidic environment for AChR–αBTx complexes. This phase (see a scheme in ref. 34) consists of planar bilayer sheets stacked in the third dimension and spaced by aqueous compartments with repeat distance that depends on various parameters like hydration, polarity of the lipid head groups, and ionic strength. A spacing distance sufficient for nesting the large hydrophilic extra-membranous domains of the receptor would allow incorporation of the receptor in the lamellar liquid-crystalline phase. The size of the extra-membranous domains and the manner by which receptors in one sheet interact with receptors in the flanking sheets would ultimately determine the spacing distance between the receptor-containing sheets, leading thereby to a multilayer organization with a specific packing pattern.

By using light microscopy and EM, the conditions necessary for reconstituting AChR–αBTx complexes in MO 3D-matrix, while maintaining the toxin associated to the receptor, were established. The appearance of birefringent polycrystalline aggregates (Fig. 1 D and E) reflects the nucleation and growth of nanocrystals (Figs. 2 and 3). The spherical particles that compose these nanocrystals correspond to AChR–αBTx complexes seen from a top view, as (i) only purified AChR–αBTx complexes were used in the reconstitution step; (ii) these complexes were stably labeled with rhodamine, a fluorophore covalently attached to αBTx; and (iii) these particles display the shape and dimensions typical of the AChR, as previously visualized in native membrane preparations (57, 26). Moreover, despite the low resolution of the applied freeze fracture/transmission EM techniques, the pit surrounded by the walls of the receptor's extracellular domain was, in most cases, readily identified (e.g., Fig. 3 A and B). Fracture planes that correspond to receptor mid-sagittal sections revealed multilayer organization of receptor molecules that are packed tail to tail as dimers (e.g., Fig. 4 A and B). The two heads of each dimer interact with the heads of two different dimers from the flanking layers, as schematically illustrated in Fig. 4D.

The low-resolution EM technique used here does not allow us to conclude on the lateral complex–complex interactions. In the case of ACh-binding protein, lateral interactions play a role in crystal packing (45), leaving no space to accommodate αBTx by the crystallized form (PDB ID number 1I9B, see crystallo-graphic symmetry). Here, it seems that there is some separation between particles (Figs. 3 and 4). Hence, crystallization of a preformed receptor–toxin complex with a different pattern of lateral interactions cannot be excluded.

As pointed out above, the fracture planes exhibit defects such as collapse of receptor particles and cracks in nanocrystals (e.g., Figs. 3 and 4). It is reasonable to assume that these defects occurred after the nanocrystals grew, due to mechanical damage taking place either when preparing the specimens for EM studies (see Material and Methods) or while fracturing through the hard proteinaceous material. We do not, however, exclude defects, such as dislocations, that might take place already during the growth of nanocrystals in the lipidic 3D matrix.

Taken together, these results demonstrate that the birefringent red material grown in the lipidic matrix consists of nanometer-sized 3D crystals of AChR–αBTx complexes. As these nanocrystals touch each other (Fig. 2 A), the growth of larger crystals is inhibited.

Notably, part of the rhodamine-labeled material does not exhibit birefringence (Fig. 1 D and E). These regions probably correspond to disordered aggregates visualized by transmission EM (data not shown). By emulsifying the lipidic matrix, we aimed at releasing single AChR–αBTx complexes from the disordered aggregates, thereby allowing them to attach to the surface of nanocrystals that detach from each other. Attachment of single molecules to a surface of a preexisting crystal is a fundamental process in crystallization of macromolecules (46). Indeed, micrometer-sized crystals appear in the emulsion. As reported in Results, the crystallization and emulsification conditions did not lead to detachment of the toxin from the receptor. Hence, as can be judged from their optical properties, these microcrystals are comprised of AChR–αBTx complexes; they display a homogeneous red color and, as expected, larger crystals display stronger red color because they contain more labeled complexes. These crystals exhibit clear facets, and they are birefringent, indicating a high degree of order.

Thus far, these reproducible crystals did not diffract x-rays, probably because they are too thin and perhaps not perfectly ordered. Nevertheless, they can readily be removed and stabilized outside the emulsion for further manipulations. Using these microcrystals as a source of preexisting crystalline surfaces (seeds) would allow decreasing the high degree of supersaturation and energy that are necessary for nucleation in aqueous (detergent) solutions (36). Thus, in a second step of crystallization, seeds prepared from these crystals will be used to trigger epitaxial growth of well-diffracting crystals directly from detergent-containing solutions, avoiding thereby the massive nucleation and precipitation that usually prevent efficient crystallization.

Finally, the ability to follow the development of nanocrystals in the MO 3D matrix, owing to their birefringent properties, and the capability to further develop them into micrometer-sized crystals, may allow the use of unlabeled protein. This procedure should pave the way for crystallization of other membrane-spanning proteins that resist crystallization.

Acknowledgments

Y.P. thanks the Human Frontier Science Program Organization, the Federation of European Biochemical Societies, and the Manlio Cantarini Foundation for postdoctoral fellowships, and Mr. I. Paas for considerable private support. This work was supported by the Collège de France, the Centre National de la Recherche Scientifique, the Association pour la Recherche contre le Cancer, and European Economic Community contracts.

Abbreviations: AChR, acetylcholine receptor; αBTx, α-bungarotoxin; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate; MO, monoolein; EM, electron microscopy.

References

  • 1.Rosenbusch, J. P. (2001) J. Struct. Biol. 136, 144–157. [DOI] [PubMed] [Google Scholar]
  • 2.Corringer, P. J., Le Novere, N. & Changeux, J. P. (2000) Annu. Rev. Pharmacol. Toxicol. 40, 431–458. [DOI] [PubMed] [Google Scholar]
  • 3.Karlin, A. (2002) Nat. Rev. Neurosci. 3, 102–114. [DOI] [PubMed] [Google Scholar]
  • 4.Engel, A. G., Ohno, K. & Sine, S. M. (2003) Nat. Rev. Neurosci. 4, 339–352. [DOI] [PubMed] [Google Scholar]
  • 5.Kistler, J. & Stroud, R. M. (1981) Proc. Natl. Acad. Sci. USA 78, 3678–3682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Brisson, A. & Unwin, P. N. (1984) J. Cell Biol. 99, 1202–1211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Unwin, N. (2000) Philos. Trans. R. Soc. London B 355, 1813–1829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Miyazawa, A., Fujiyoshi, Y. & Unwin, N. (2003) Nature 423, 949–955. [DOI] [PubMed] [Google Scholar]
  • 9.Poulter, L., Earnest, J. P., Stroud, R. M. & Burlingame, A. L. (1989) Proc. Natl. Acad. Sci. USA 86, 6645–6649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Landau, E. M. & Rosenbusch, J. P. (1996) Proc. Natl. Acad. Sci. USA 93, 14532–14535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Pebay-Peyroula, E., Rummel, G., Rosenbusch, J. P. & Landau, E. M. (1997) Science 277, 1676–1681. [DOI] [PubMed] [Google Scholar]
  • 12.Luecke, H., Schobert, B., Richter, H. T., Cartailler, J. P. & Lanyi, J. K. (1999) Science 286, 255–261. [DOI] [PubMed] [Google Scholar]
  • 13.Kolbe, M., Besir, H., Essen, L. O. & Oesterhelt, D. (2000) Science 288, 1390–1396. [DOI] [PubMed] [Google Scholar]
  • 14.Luecke, H., Schobert, B., Lanyi, J. K., Spudich, E. N. & Spudich, J. L. (2001) Science 293, 1499–1503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Royant, A., Nollert, P., Edman, K., Neutze, R., Landau, E. M., Pebay-Peyroula, E. & Navarro, J. (2001) Proc. Natl. Acad. Sci. USA 98, 10131–10136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Neubig, R. R., Krodel, E. K., Boyd, N. D. & Cohen, J. B. (1979) Proc. Natl. Acad. Sci. USA 76, 690–694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Karlin, A. & Cowburn, D. (1973) Proc. Natl. Acad. Sci. USA 70, 3636–3640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Damle, V. N., McLaughlin, M. & Karlin, A. (1978) Biochem. Biophys. Res. Commun. 84, 845–851. [DOI] [PubMed] [Google Scholar]
  • 19.Reynolds, J. A. & Karlin, A. (1978) Biochemistry 17, 2035–2038. [DOI] [PubMed] [Google Scholar]
  • 20.Chang, H. W. & Bock, E. (1977) Biochemistry 16, 4513–4520. [DOI] [PubMed] [Google Scholar]
  • 21.Hamilton, S. L., McLaughlin, M. & Karlin, A. (1977) Biochem. Biophys. Res. Commun. 79, 692–699. [DOI] [PubMed] [Google Scholar]
  • 22.Martinez, K., Gohon, Y., Corringer, P., Tribet, C., Merola, F., Changeux, J. & Popot, J. (2002) FEBS Lett. 528, 251–256. [DOI] [PubMed] [Google Scholar]
  • 23.Conti-Tronconi, B. M., Tang, F., Walgrave, S. & Gallagher, W. (1990) Biochemistry 29, 1046–1054. [DOI] [PubMed] [Google Scholar]
  • 24.McCarthy, M. P. & Moore, M. A. (1992) J. Biol. Chem. 267, 7655–7663. [PubMed] [Google Scholar]
  • 25.Rummel, G., Hardmeyer, A., Widmer, C., Chiu, M. L., Nollert, P., Locher, K. P., Pedruzzi, I. I., Landau, E. M. & Rosenbusch, J. P. (1998) J. Struct. Biol. 121, 82–91. [DOI] [PubMed] [Google Scholar]
  • 26.Cartaud, J., Benedetti, E. L., Sobel, A. & Changeux, J. P. (1978) J. Cell Sci. 29, 313–337. [DOI] [PubMed] [Google Scholar]
  • 27.Changeux, J. P., Kasai, M. & Lee, C. Y. (1970) Proc. Natl. Acad. Sci. USA 67, 1241–1247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Lester, H. A. (1970) Nature 227, 727–728. [DOI] [PubMed] [Google Scholar]
  • 29.Lester, H. A. (1972) Mol. Pharmacol. 8, 623–631. [PubMed] [Google Scholar]
  • 30.Meunier, J. C., Olsen, R. W., Menez, A., Fromageot, P., Boquet, P. & Changeux, J. P. (1972) Biochemistry 11, 1200–1210. [DOI] [PubMed] [Google Scholar]
  • 31.Prives, J. M., Reiter, M. J., Cowburn, D. A. & Karlin, A. (1972) Mol. Pharmacol. 8, 786–789. [PubMed] [Google Scholar]
  • 32.Taylor, P., Osaka, H., Molles, B. E., Sugiyama, N., Marchot, P., Ackermann, E. J., Malany, S., McArdle, J. J., Sine, S. M. & Tsigelny, I. (1998) J. Physiol. (Paris) 92, 79–83. [DOI] [PubMed] [Google Scholar]
  • 33.Luzzati, V. (1997) Curr. Opin. Struct. Biol. 7, 661–668. [DOI] [PubMed] [Google Scholar]
  • 34.Caffrey, M. (2003) J. Struct. Biol. 142, 108–132. [DOI] [PubMed] [Google Scholar]
  • 35.Landau, E. M., Rummel, G., Cowan-Jacob, S. W. & Rosenbusch, J. P. (1997) J. Phys. Chem. B 101, 1935–1937. [Google Scholar]
  • 36.Ducruix, A. & Giege, R. (1992) Crystallization of Nucleic Acid and Protein: A Practical Approach (Oxford Univ. Press, Oxford).
  • 37.Toyoshima, C. & Unwin, N. (1988) Nature 336, 247–250. [DOI] [PubMed] [Google Scholar]
  • 38.Gouaux, E. (1998) Structure 6, 5–10. [DOI] [PubMed] [Google Scholar]
  • 39.Nollert, P., Qiu, H., Caffrey, M., Rosenbusch, J. P. & Landau, E. M. (2001) FEBS Lett. 504, 179–186. [DOI] [PubMed] [Google Scholar]
  • 40.Harel, M., Kasher, R., Nicolas, A., Guss, J. M., Balass, M., Fridkin, M., Smit, A. B., Brejc, K., Sixma, T. K., Katchalski-Katzir, E., et al. (2001) Neuron 32, 265–275. [DOI] [PubMed] [Google Scholar]
  • 41.Fruchart-Gaillard, C., Gilquin, B., Antil-Delbeke, S., Le Novere, N., Tamiya, T., Corringer, P. J., Changeux, J. P., Menez, A. & Servent, D. (2002) Proc. Natl. Acad. Sci. USA 99, 3216–3221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Moise, L., Piserchio, A., Basus, V. J. & Hawrot, E. (2002) J. Biol. Chem. 277, 12406–12417. [DOI] [PubMed] [Google Scholar]
  • 43.Samson, A. O., Scherf, T., Eisenstein, M., Chill, J. H. & Anglister, J. (2002) Neuron 35, 319–332. [DOI] [PubMed] [Google Scholar]
  • 44.Smit, A. B., Syed, N. I., Schaap, D., van Minnen, J., Klumperman, J., Kits, K. S., Lodder, H., van der Schors, R. C., van Elk, R., Sorgedrager, B., et al. (2001) Nature 411, 261–268. [DOI] [PubMed] [Google Scholar]
  • 45.Brejc, K., van Dijk, W. J., Klaassen, R. V., Schuurmans, M., van Der Oost, J., Smit, A. B. & Sixma, T. K. (2001) Nature 411, 269–276. [DOI] [PubMed] [Google Scholar]
  • 46.Yau, S. T. & Vekilov, P. G. (2000) Nature 406, 494–497. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES